AFMD - AbCheck develops microfluidics tech for antibody discovery under Czech grant pact

2023-03-09 05:55:25 ET

• Affimed's ( NASDAQ: AFMD ) unit AbCheck said it has completed the technology development activities under a 2019 research grant agreement with the Ministry of Industry and Trade of the Czech Republic.
• AbCheck, which is focused on antibody discovery, had received more than €1M.
• The grant was titled, 'Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect,' according to the company.
• AbCheck said it successfully developed a novel microfluidics technology for functional antibody discovery.
• The company noted that it not only met all goals of the original project, but successfully developed its novel microfluidics technology beyond the scope of the plan.
• Besides the planned screening assays for agonistic antibodies in rabbit models, several functional assays were also developed in chicken and mouse models, according to the company.
• "We are grateful to the Ministry of Industry and Trade of the Czech Republic for having supported the development of this novel technology, which enables AbCheck to identify functional antibodies with unique features and properties much faster than legacy technologies such as phage or yeast display," said AbCheck Managing Director Volker Lang.

For further details see: